Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + Dexamethasone in Relapsed/Refractory AL Amyloidosis
NCT04984330Phase 1Withdrawn
- Sponsor
- Weill Cornell Medicine
- Start
- Dec 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in amyloid light chain amyloidosis, sponsored by Weill Cornell Medicine. Primary endpoint: Dose Limiting Toxicity at 12 months. Planned start Dec 2021; status: withdrawn.
02
Drugs
selinexor
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT04984330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984330.